DE69814089D1 - Verwendung von einem draflazin analog zur schmerzbehandlung - Google Patents

Verwendung von einem draflazin analog zur schmerzbehandlung

Info

Publication number
DE69814089D1
DE69814089D1 DE69814089T DE69814089T DE69814089D1 DE 69814089 D1 DE69814089 D1 DE 69814089D1 DE 69814089 T DE69814089 T DE 69814089T DE 69814089 T DE69814089 T DE 69814089T DE 69814089 D1 DE69814089 D1 DE 69814089D1
Authority
DE
Germany
Prior art keywords
phenyl
treatment
derivative
4alkyl
aminocarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69814089T
Other languages
English (en)
Other versions
DE69814089T2 (de
Inventor
Frans Meert
Belle Herman Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE69814089D1 publication Critical patent/DE69814089D1/de
Application granted granted Critical
Publication of DE69814089T2 publication Critical patent/DE69814089T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69814089T 1997-06-16 1998-06-09 Verwendung von einem draflazin analog zur schmerzbehandlung Expired - Fee Related DE69814089T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97201813 1997-06-16
EP97201813 1997-06-16
PCT/EP1998/003664 WO1998057643A1 (en) 1997-06-16 1998-06-09 Use of draflazine-analogues for treating pain

Publications (2)

Publication Number Publication Date
DE69814089D1 true DE69814089D1 (de) 2003-06-05
DE69814089T2 DE69814089T2 (de) 2004-02-19

Family

ID=8228446

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69814089T Expired - Fee Related DE69814089T2 (de) 1997-06-16 1998-06-09 Verwendung von einem draflazin analog zur schmerzbehandlung

Country Status (10)

Country Link
US (1) US6403589B1 (de)
EP (1) EP0999840B1 (de)
JP (1) JP2002504134A (de)
KR (1) KR20010013387A (de)
AT (1) ATE238794T1 (de)
AU (1) AU8438798A (de)
CA (1) CA2294011A1 (de)
DE (1) DE69814089T2 (de)
ES (1) ES2199447T3 (de)
WO (1) WO1998057643A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02006137A (es) * 1999-12-20 2002-12-05 Neuromed Tech Inc Bloqueadores del canal de calcio parcialmente saturados.
PT1539124T (pt) * 2002-09-05 2018-10-22 Vanderbilt Royalty Sub L P Composições e kits para a remoção de compostos irritantes de superfícies corporais
JPWO2004101593A1 (ja) * 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 5’−修飾ヌクレオシド誘導体及びその医薬用途
EA013056B1 (ru) * 2005-04-01 2010-02-26 Ньюроджесэкс, Инк. Масла капсаициноидов и способы их получения и применения
WO2011000945A2 (en) 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
PE20161476A1 (es) 2014-06-26 2017-01-07 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
CN108349942B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物
JP6857662B2 (ja) 2015-11-06 2021-04-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft インドリン−2−オン誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2368280A1 (fr) 1976-10-20 1978-05-19 Theramex Nouvelle composition therapeutique presentant une activite anti-agregante plaquettaire, et son procede de preparation
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
FR2513118A1 (fr) 1981-09-18 1983-03-25 Rocador Sa Composition pharmaceutique a base de dipyridamol et de sel d'aluminium de l'acide acetylsalicylique pour combattre l'agregation plaquettaire
NZ223847A (en) 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions
US5236908A (en) 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
IL108524A0 (en) 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs

Also Published As

Publication number Publication date
AU8438798A (en) 1999-01-04
EP0999840A1 (de) 2000-05-17
US6403589B1 (en) 2002-06-11
ATE238794T1 (de) 2003-05-15
JP2002504134A (ja) 2002-02-05
KR20010013387A (ko) 2001-02-26
CA2294011A1 (en) 1998-12-23
DE69814089T2 (de) 2004-02-19
WO1998057643A1 (en) 1998-12-23
ES2199447T3 (es) 2004-02-16
EP0999840B1 (de) 2003-05-02

Similar Documents

Publication Publication Date Title
LV12209A (lv) Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori
EA199700135A1 (ru) Ингибиторы клеточной адгезии
MXPA04000334A (es) Compuestos de alquilamida n-(3-amino-2-hidroxi-propil) substituidos.
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
ATE538794T1 (de) Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
PT705100E (pt) Guanidinas substituidas terapeuticas
BR9809185A (pt) Diidropiranos fundidos
NO990662L (no) Trombin-inhibitorer
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
NO983991L (no) Serin-protease-inhibitorer
DE69814089D1 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
GB9907571D0 (en) Compounds
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
BR9611520A (pt) Composto hemo-reguladores.
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU93045696A (ru) Ингибиторы протеазы вируса иммунодефицита человека, полезные для лечения спида

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee